Advisor(s)
Abstract(s)
As Gamapatias Monoclonais resultam de uma expansão clonal de células B que produzem e secretam imunoglobulinas monoclonais (Kappa ou Lambda), ou fragmento dessa chamada proteína M. O diagnóstico é baseado na combinação de características clínicas, laboratoriais e imagiológicas.
A avaliação do prognóstico é mandatória para selecção da melhor estratégia terapêutica, especialmente quando se decidem tratamentos com elevada morbilidade e/ou mortalidade, como transplante de medula óssea. Um bom sistema de estadiamento é importante na decisão terapêutica. A β2-m sérica constitui um bom marcador para o prognóstico do Mieloma Múltiplo.
A β2-m pode ser doseada por nefelometria no soro dos doentes. Actualmente passou a ser possível a sua detecção nos plasmócitos por imunofenotipagem por Citometria de Fluxo.
Este estudo tem como principal objectivo avaliar se existe associação da β2-m em doentes com Mieloma Múltiplo por dois métodos: nefelometria e citometria de fluxo.
Foi realizado um estudo retrospectivo destes doentes, em que foram estudadas 88 amostras. Doseou-se a β2-m sérica por nefelometria e a β2-m na superfície dos plasmócitos por citometria de fluxo.
Os resultados obtidos foram posteriormente analisados estatisticamente onde se encontraram diferenças estatisticamente significativas entre os dois métodos nas amostras com plasmócitos anormais (p<0,001), quando efetuada a correlação de Pearson, obteve-se uma correlação negativa fraca em todas as amostras (p<-0,144).
A β2-m celular torna-se um marcador adicional, muito importante, de prognóstico no Mielaoma Múltiplo.
Monoclonal Gammophathy results of a B cell clonal expansion that produces and secrets monoclonal immunoglobulines or a immunoglobulin fragment called M protein. The diagnosis is based on the combination of clinical, laboratorial and immagiological characteristics. In order to get the best therapeutic strategy a prognostics evaluation is mandatory, especially when the chosen treatments have rates of morbidity and mortality, like, for example, bone marrow transplants. A good staging system is essential for the therapeutic decision. The beta-2 microglobulin (β2-m) constitutes a good marker for the Multiple Myeloma prognostic. β2-m can be dosed by Nephelometry in the patient`s serum. Nowadays it is possible to detected β2-m in the plasma cells by Immunophenotyping by Flow Citometry. The objective of this study is to verify if there is an association of β2-m in patients with Multiple Myeloma with two distinct methods: Nephelometry and Flow Citometry. Retrospectively we studied 88 patients samples. The β2-m was dosed in the serum by Nephelometry and determined in the surface of the plasma cells by Flow Citometry.. The obtained results were then statiscally analysed when there were statiscally significant differences between the two methods in the samples with abnormal plasma cells (p<0,001), in Pearson correlation were obtained a week negative correlation in all samples (p<-0.144). β2-m determined in the surface of the plasma cells become an important aditional prognostic marker.
Monoclonal Gammophathy results of a B cell clonal expansion that produces and secrets monoclonal immunoglobulines or a immunoglobulin fragment called M protein. The diagnosis is based on the combination of clinical, laboratorial and immagiological characteristics. In order to get the best therapeutic strategy a prognostics evaluation is mandatory, especially when the chosen treatments have rates of morbidity and mortality, like, for example, bone marrow transplants. A good staging system is essential for the therapeutic decision. The beta-2 microglobulin (β2-m) constitutes a good marker for the Multiple Myeloma prognostic. β2-m can be dosed by Nephelometry in the patient`s serum. Nowadays it is possible to detected β2-m in the plasma cells by Immunophenotyping by Flow Citometry. The objective of this study is to verify if there is an association of β2-m in patients with Multiple Myeloma with two distinct methods: Nephelometry and Flow Citometry. Retrospectively we studied 88 patients samples. The β2-m was dosed in the serum by Nephelometry and determined in the surface of the plasma cells by Flow Citometry.. The obtained results were then statiscally analysed when there were statiscally significant differences between the two methods in the samples with abnormal plasma cells (p<0,001), in Pearson correlation were obtained a week negative correlation in all samples (p<-0.144). β2-m determined in the surface of the plasma cells become an important aditional prognostic marker.
Description
Keywords
Citometria de fluxo Nefelometria β2-microglobulina Gamapatias monoclonais Mieloma múltiplo Flow citometry Nephelomethry β2-microglobulline Monoclonal Gammophathy Multiple myeloma